Products we won't recommend

By MenoVerdict editorial team

Every recommendation on this site is set by the evidence first, and the commercial relationship — if any — second. Our editorial policy and evidence grading method explain the process; this page lists the specific categories we reject outright, and why.

The standard we hold every claim to

The Federal Trade Commission's staff guidance on health product advertising requires that health and safety claims be truthful, not misleading, and backed by competent and reliable scientific evidence before an ad ever runs, and holds advertisers responsible for substantiating every claim they make, directly or by implication. We hold ourselves to that same bar before recommending anything, whether or not it would earn us a commission.

Categories we reject

  • Custom-compounded "bioidentical" hormone products marketed as safer or more natural than FDA-approved hormone therapy. ACOG's 2023 clinical consensus recommends against routinely prescribing these when FDA-approved options exist, given the lack of standardized testing and a marketing framing that isn't backed by evidence. See our full explainer: bioidentical vs. compounded hormones.
  • At-home hormone testing kits marketed to self-diagnose menopause stage or guide treatment decisions. Clinical guidelines do not support using these tests to identify perimenopause or menopause in the way they're commonly marketed.
  • Hormone pellets marketed with unverified dosing claims, outside of a monitored clinical setting.
  • "Hormone balance" supplements that imply a multi-ingredient blend can correct hormonal fluctuation. This phrase itself fails basic scrutiny — see our evidence verdict on these products specifically.
  • Diet pills, "metabolism boosters," and detox products marketed for menopausal weight gain. We cover what's actually linked to midlife weight changes, and what has real evidence, on our weight gain page — none of it is a pill.
  • "Vaginal rejuvenation" devices and procedures marketed for genitourinary symptoms, where evidence doesn't support the claims made.
  • Any product using before-and-after claims, fake urgency, countdowns, or invented scarcity — regardless of category, this marketing style itself is disqualifying under our editorial policy.

What this doesn't mean

Rejecting a category as commonly marketed isn't the same as saying every individual product or ingredient within it is worthless for everyone. Our Does It Work? evidence directory grades specific products and ingredients individually, with the nuance the evidence actually supports — strong, moderate, limited, not supported, or harm concern. The categories above are ones where the marketing claims themselves, as a pattern, outrun any version of the evidence we've been able to verify.

Something we missed?

If you've seen a product marketed in a way that concerns you, or one you think deserves its own evidence verdict, reach out through our contact page. Before trying anything new, our symptoms checklist can help you pin down what you're actually trying to treat.

Where are you right now?

Still tracking

Not sure if your symptoms fit? Start tracking your daily patterns.

Log and spot your patterns with the symptom checklist →

Ready to talk to a doctor

Have an upcoming appointment? Bring structured questions and your history.

Prepare your 10-minute doctor appointment questions →

Already on treatment

Evaluating your response or wondering what to adjust next?

Explore evidence-graded treatment and lifestyle options →

Questions people ask

Why would an evidence-based site refuse to recommend a product even if it could earn a commission?

Because our editorial policy sets the evidence grade before checking whether an affiliate programme exists. If a category of product fails that standard, no commission changes the verdict — we say so, and reject it, in public.

Does this mean every supplement on this list is useless for everyone?

No — it means the category, as commonly marketed for menopause, lacks the kind of evidence (competent and reliable scientific evidence, per FTC standards) needed to recommend it as a treatment. Individual products within a graded category are assessed on our Does It Work? pages, where the evidence allows for more nuance.

References

  1. Health Products Compliance Guidance. Federal Trade Commission, 2022.
  2. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. American College of Obstetricians and Gynecologists' Committee on Clinical Consensus-Gynecology, 2023.
Change log
  • : Published products-we-won't-recommend policy page